Search research articles
Contact Us
Filters
Showing results (111-120 of 121) with videos related to
Page
of 13
Sort By:
British Journal of Cancer
|
July 4, 2025
AKT/mTOR as a targetable hub to overcome multimodal resistance to EGFR inhibitors in oesophageal squamous cell carcinoma
Lindsay C Spender, Dale M Watt, Mark A Baxter, et al.
Journal of Gastrointestinal Oncology
|
January 12, 2026
Trifluridine/tipiracil (FTD/TPI) in advanced gastric cancer-a retrospective cohort study providing real-world survival and safety data from the United Kingdom
Joseph Salf, Aimee Cunningham, Dinakshi Shah, et al.
British Journal of Cancer
|
December 2, 2015
Tumour expression of leptin is associated with chemotherapy resistance and therapy-independent prognosis in gastro-oesophageal adenocarcinomas
G H Bain, E Collie-Duguid, G I Murray, et al.
The Lancet. Oncology
|
June 22, 2014
Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial
Susan J Dutton, David R Ferry, Jane M Blazeby, et al.
British Journal of Cancer
|
May 27, 2016
Tumour expression of leptin is associated with chemotherapy resistance and therapy-independent prognosis in gastro-oesophageal adenocarcinomas
G H Bain, E Collie-Duguid, G I Murray, et al.
British Journal of Cancer
|
February 27, 2014
Tumour expression of leptin is associated with chemotherapy resistance and therapy-independent prognosis in gastro-oesophageal adenocarcinomas
G H Bain, E Collie-Duguid, G I Murray, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 25, 2017
Gefitinib and EGFR Gene Copy Number Aberrations in Esophageal Cancer
Russell D Petty, Asa Dahle-Smith, David A J Stevenson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 31, 2012
Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report
A F C Okines, R E Langley, L C Thompson, et al.
ESMO Open
|
May 14, 2024
An investigation of the clinical impact and therapeutic relevance of a DNA damage immune response (DDIR) signature in patients with advanced gastroesophageal adenocarcinoma
M A Baxter, L C Spender, D Cairns, et al.
ESMO Open
|
October 12, 2024
Immune microenvironment modulation following neoadjuvant therapy for oesophageal adenocarcinoma: a translational analysis of the DEBIOC clinical trial
E Scanlon, A Lavery, M Albraikat, et al.
Page
of 13
Search research articles
Search
Showing results (111-120 of 121) with videos related to
Sort By:
Page
of 13
British Journal of Cancer
|
July 4, 2025
AKT/mTOR as a targetable hub to overcome multimodal resistance to EGFR inhibitors in oesophageal squamous cell carcinoma
Lindsay C Spender, Dale M Watt, Mark A Baxter, et al.
Journal of Gastrointestinal Oncology
|
January 12, 2026
Trifluridine/tipiracil (FTD/TPI) in advanced gastric cancer-a retrospective cohort study providing real-world survival and safety data from the United Kingdom
Joseph Salf, Aimee Cunningham, Dinakshi Shah, et al.
British Journal of Cancer
|
December 2, 2015
Tumour expression of leptin is associated with chemotherapy resistance and therapy-independent prognosis in gastro-oesophageal adenocarcinomas
G H Bain, E Collie-Duguid, G I Murray, et al.
The Lancet. Oncology
|
June 22, 2014
Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial
Susan J Dutton, David R Ferry, Jane M Blazeby, et al.
British Journal of Cancer
|
May 27, 2016
Tumour expression of leptin is associated with chemotherapy resistance and therapy-independent prognosis in gastro-oesophageal adenocarcinomas
G H Bain, E Collie-Duguid, G I Murray, et al.
British Journal of Cancer
|
February 27, 2014
Tumour expression of leptin is associated with chemotherapy resistance and therapy-independent prognosis in gastro-oesophageal adenocarcinomas
G H Bain, E Collie-Duguid, G I Murray, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 25, 2017
Gefitinib and EGFR Gene Copy Number Aberrations in Esophageal Cancer
Russell D Petty, Asa Dahle-Smith, David A J Stevenson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 31, 2012
Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report
A F C Okines, R E Langley, L C Thompson, et al.
ESMO Open
|
May 14, 2024
An investigation of the clinical impact and therapeutic relevance of a DNA damage immune response (DDIR) signature in patients with advanced gastroesophageal adenocarcinoma
M A Baxter, L C Spender, D Cairns, et al.
ESMO Open
|
October 12, 2024
Immune microenvironment modulation following neoadjuvant therapy for oesophageal adenocarcinoma: a translational analysis of the DEBIOC clinical trial
E Scanlon, A Lavery, M Albraikat, et al.
Page
of 13